Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Equinor ASA (EQNR) vs Twist Bioscience Corp (TWST) Price & Performance

Equinor ASATrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Equinor ASA vs Twist Bioscience Corp — how do they compare? Equinor ASA trades at $43 (market cap $101.62B), while Twist Bioscience Corp trades at $154.2 (market cap $10.08B). The key difference: Equinor ASA is far larger — about 10.1× Twist Bioscience Corp's market cap, and Equinor ASA pays a 3.63% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Twist Bioscience Corp for 27 Days on average.

EQNRTWST
Market Cap
$101.62B$10.08B
Volume
4,991,7824,229,037
Sector
EnergyHealth
52-Week High
$45.75$205.00
52-Week Low
$22.41$25.45
Typical Hold Time
59 Days27 Days
Enterprise Value
$110.31B$10.01B
Dividend Yield
3.63%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Equinor ASA

Equinor (EQNR) trades at $41.61, down 3.26% today, with a bearish technical signal despite strong valuation metrics including a P/E of 11.28 and EV/EBITDA of 2.35. The company has beaten earnings estimates in two of the last three quarters, with Q3 2026 results pending. Recent news highlights expansion in LNG and carbon capture projects, while cash flow trends show improving operational performance from 2025 levels.

EQNR presents a compelling value opportunity with significant upside to the $70.50 consensus price target, though near-term technical weakness and declining profit margins from 2022 peaks pose risks. The stock's 21.32% ROE and dividend payments support income investors, while LNG expansion plans provide growth catalysts. Market sentiment remains mixed with 30% buy ratings amid energy sector volatility.

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.

The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EQNR
53% Buy47% Sell
Avg holding period · 59 Days
TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Equinor ASA

Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.

Read more on EQNR →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →